# Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

> **NCT02956421** · PHASE2 · COMPLETED · sponsor: **Yisheng Biopharma (Singapore) Pte. Ltd.** · enrollment: 126 (actual)

## Conditions studied

- Rabies

## Interventions

- **BIOLOGICAL:** RABIPUR®
- **BIOLOGICAL:** PIKA rabies vaccine

## Key facts

- **NCT ID:** NCT02956421
- **Lead sponsor:** Yisheng Biopharma (Singapore) Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02956421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02956421, "Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02956421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*